Sanfang Tu

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

Li Xuan, Yu Wang, Fen Huang et al. · The Lancet Oncology · 2020 · 310 citations

Hematological Malignancy, Transplantation, Marrow Transplantation +10

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Hui Liu, Xiao Zhai, Zhaoyang Song et al. · Journal of Hematology & Oncology · 2013 · 105 citations · Full text

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Sanfang Tu, Xuan Zhou, Zhenling Guo et al. · Frontiers in Oncology · 2019 · 77 citations · Full text

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

Li Xuan, Yu Wang, Kaibo Yang et al. · The Lancet Haematology · 2023 · 63 citations

Hematological Malignancy, Oncology, Marrow Transplantation +10

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Xuan Zhou, Sanfang Tu, Chunsheng Wang et al. · Frontiers in Immunology · 2020 · 50 citations · Full text